ArticleDiscover oncology2025
A surgical strategy-based nomogram for primary pulmonary mucoepidermoid carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary pulmonary mucoepidermoid carcinoma (PMEC) is a rare malignancy with no standardized prognostic tools. This study aimed to investigate whether specific surgical approaches significantly impact survival outcomes and to develop an accurate predictive nomogram incorporating surgical variables.
methodsUsing the SEER database (2004-2020), we identified 225 PMEC patients. Independent prognostic factors were selected via Cox regression (P < 0.05). A nomogram was developed and validated using time-dependent ROC curves, calibration plots, and decision curve analysis (DCA).
resultsWe analyzed 225 PMEC cases, predominantly affecting patients aged 30-69 years with slight male predominance. Most tumors (30-52 mm) were early-stage with favorable prognosis; only 11.01% presented as Stage IV (3-year OS: 18.5%, median survival: 8.5 months). The nomogram (incorporating age, tumor size, N/M stage, surgery, and chemotherapy) demonstrated excellent discrimination (AUC > 0.9) and calibration, with pneumonectomy plus lymph node dissection showing the best surgical outcomes.
conclusionOur nomogram provides a clinically useful tool for PMEC prognostication, validating that lymph node dissection during lobectomy significantly improves survival. It may guide individualized surgical decisions for this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.